Accretion Nutraveda Ltd vs Zenith Drugs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Accretion Nutraveda Ltd is ₹ 267.5 as of 29 Apr 15:30 . The P/E Ratio of Accretion Nutraveda Ltd is 0 as of March 2022 .The P/E Ratio of Zenith Drugs Ltd is 0 as of March 2022 . The Market Cap of Accretion Nutraveda Ltd is ₹ 0 crore as of March 2022 .The Market Cap of Zenith Drugs Ltd is ₹ 0 crore as of March 2022 . The Dividend Payout of Accretion Nutraveda Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Zenith Drugs Ltd changed from 8.99 % on March 2024 to 0 % on March 2025 . This represents a CAGR of -100.00% over 2 years .

About Accretion Nutraveda Ltd

Accretion Nutraveda Limited was initially incorporated as a Private Limited Company on March 16, 2021 and has subsequently, converted the status into a Public Limited Company vide Certificate of Incorporation issued by the Registrar of Companies, Central Processing Centre w.e.f.
May 2, 2025. The Company, established at Ahmedabad, is a healthcare-focused Contract Development and Manufacturing Organization (CDMO), offering specialized services to a diverse range of clients across the various industries.
It specialize in ayurvedic and nutraceutical products including Tablets, Capsules, Oral Liquids, Oral Powders, External Preparation and Oils.
Apart from these, it offer a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. The products include Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.

About Zenith Drugs Ltd

Zenith Drugs Ltd was originally incorporated on November 15, 2000 as a Private Limited Company in the name of 'Zenith Drugs Private Limited' issued by the Registrar of Companies, in the State of Madhya Pradesh, Gwalior.
Subsequently, Company was converted into Public Limited and consequently, the name of Company was changed to Zenith Drugs Limited' pursuance to issuance of a Fresh Certificate of Incorporation on September 13, 2023 by the Registrar of Companies, Gwalior. Zenith are a reputable pharmaceutical manufacturing and trading unit based out from Indore.
With a diverse portfolio of formulations, the Company is specialized in manufacturing affordable and high quality medicines to meet the needs of patients.
The Company is mainly engaged in the business of manufacturing and Trading of Medicines.

FAQs for the comparison of Accretion Nutraveda Ltd and Zenith Drugs Ltd

Which company has a larger market capitalization, Accretion Nutraveda Ltd or Zenith Drugs Ltd?

Market cap of Accretion Nutraveda Ltd is 193 Cr while Market cap of Zenith Drugs Ltd is 77 Cr

What are the key factors driving the stock performance of Accretion Nutraveda Ltd and Zenith Drugs Ltd?

The stock performance of Accretion Nutraveda Ltd and Zenith Drugs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Accretion Nutraveda Ltd and Zenith Drugs Ltd?

As of May 4, 2026, the Accretion Nutraveda Ltd stock price is INR ₹267.5. On the other hand, Zenith Drugs Ltd stock price is INR ₹45.35.

How do dividend payouts of Accretion Nutraveda Ltd and Zenith Drugs Ltd compare?

To compare the dividend payouts of Accretion Nutraveda Ltd and Zenith Drugs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.